AIM: To investigate the role of CXCL16 in the pathogenesis of immunological liver injury and to explore the possible mechanism of T lymphocyte infiltration regulated by CXCL16. METHODS: Immunological liver injury in murine model was induced by Bacille Calmette-Guerin and lipopolysaccharide. Expression pattern and distribution of CXCL16 were examined by real-time quantitative RT-PCR and immunohistochemical analysis. Anti-CXCL16 antibody was administrated in vivo to investigate its effect on T-cell recruitment and acute hepatic necrosis. The survival of murine model was also evaluated. RESULTS: The murine immunological liver injury model was successfully established. CXCL16 expression increased and predominantly distributed in periportal areas and vascular endothelia in injured liver tissues. Administration of anti-CXCL16 Ab protected the mice from death and acute liver damage. Approximately 70% of the mice survived for 72 h in the anti-CXCL16 Ab treatment group, whereas 80% died within 72 h in control Ab group. The number of liver-infiltrating T lymphocytes was significantly reduced from 1.01 x 10(7) to 3.52 x 10(6)/liver, compared with control Ab treatment. CONCLUSION: CXCL16 is involved in immunological liver injury by regulating T lymphocyte infiltration in liver tissue.
AIM: To investigate the role of CXCL16 in the pathogenesis of immunological liver injury and to explore the possible mechanism of T lymphocyte infiltration regulated by CXCL16. METHODS:Immunological liver injury in murine model was induced by Bacille Calmette-Guerin and lipopolysaccharide. Expression pattern and distribution of CXCL16 were examined by real-time quantitative RT-PCR and immunohistochemical analysis. Anti-CXCL16 antibody was administrated in vivo to investigate its effect on T-cell recruitment and acute hepatic necrosis. The survival of murine model was also evaluated. RESULTS: The murineimmunological liver injury model was successfully established. CXCL16 expression increased and predominantly distributed in periportal areas and vascular endothelia in injured liver tissues. Administration of anti-CXCL16 Ab protected the mice from death and acute liver damage. Approximately 70% of the mice survived for 72 h in the anti-CXCL16 Ab treatment group, whereas 80% died within 72 h in control Ab group. The number of liver-infiltrating T lymphocytes was significantly reduced from 1.01 x 10(7) to 3.52 x 10(6)/liver, compared with control Ab treatment. CONCLUSION: CXCL16 is involved in immunological liver injury by regulating T lymphocyte infiltration in liver tissue.
Authors: R Nakagawa; I Nagafune; Y Tazunoki; H Ehara; H Tomura; R Iijima; K Motoki; M Kamishohara; S Seki Journal: J Immunol Date: 2001-06-01 Impact factor: 5.422
Authors: K Matsui; T Yoshimoto; H Tsutsui; Y Hyodo; N Hayashi; K Hiroishi; N Kawada; H Okamura; K Nakanishi; K Higashino Journal: J Immunol Date: 1997-07-01 Impact factor: 5.422
Authors: A Kajdacsy-Balla; E M Doi; M R Lerner; W D Bales; L T Archer; P R Wunder; M F Wilson; D J Brackett Journal: Shock Date: 1996-05 Impact factor: 3.454
Authors: H Yoneyama; A Harada; T Imai; M Baba; O Yoshie; Y Zhang; H Higashi; M Murai; H Asakura; K Matsushima Journal: J Clin Invest Date: 1998-12-01 Impact factor: 14.808
Authors: J Nagakawa; I Hishinuma; K Hirota; K Miyamoto; T Yamanaka; K Tsukidate; K Katayama; I Yamatsu Journal: Gastroenterology Date: 1990-09 Impact factor: 22.682
Authors: K Ando; T Moriyama; L G Guidotti; S Wirth; R D Schreiber; H J Schlicht; S N Huang; F V Chisari Journal: J Exp Med Date: 1993-11-01 Impact factor: 14.307
Authors: Alexander Wehr; Christer Baeck; Florian Ulmer; Nikolaus Gassler; Kanishka Hittatiya; Tom Luedde; Ulf Peter Neumann; Christian Trautwein; Frank Tacke Journal: PLoS One Date: 2014-11-05 Impact factor: 3.240
Authors: Merav Darash-Yahana; John W Gillespie; Stephen M Hewitt; Yun-Yun K Chen; Shin Maeda; Ilan Stein; Satya P Singh; Roble B Bedolla; Amnon Peled; Dean A Troyer; Eli Pikarsky; Michael Karin; Joshua M Farber Journal: PLoS One Date: 2009-08-19 Impact factor: 3.240